LIVZON PHARMA adjusts the maximum cost of acquiring its Vietnamese peer to RMB 1.85 billion

AASTOCKS
2025.12.30 14:13

LIVZON PHARMA (01513.HK) announced that it has entered into a supplemental agreement with the sellers SK Investment, Sunrise, and KBA regarding the acquisition of a total of 64.81% equity in the Vietnamese listed company Imexpharm Corporation, extending the completion date to June 30, 2026. The adjusted maximum cash consideration for this transaction is 6.891 trillion Vietnamese Dong (approximately 1.846 billion RMB)

Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer